Showing 15 posts of 129 posts found.

BMS’ Opdivo accepted to UK early access scheme

June 30, 2015
Sales and Marketing BMS, Cancer, NSCLC, eams, keytruda, opdivo

Bristol-Myers Squibb has scored another first with its new-generation oncology therapy Opdivo, which has become the first lung cancer drug …

AZ image

AstraZeneca lung drug shines on

June 1, 2015
Sales and Marketing ASCO, AZD9291, AstraZeneca, MEDI4736, NSCLC, Tafinlar

AstraZeneca’s investigational drug AZD9291 is continuing to impress, with results announced at cancer conference ASCO building on its previous ‘unprecedented’ …


BMS’ Opdivo improves lung cancer survival

May 29, 2015
Research and Development, Sales and Marketing ASCO, BMS, Bristol-Myers Squibb, NSCLC, lung cancer, nivolumab, non-small cell lung cancer, opdivo

A Phase III trial of Bristol-Myers Squibb’s immunotherapy Opdivo has found it increases overall survival in people with a common …

Pfizer image

Two oncology successes for Pfizer

April 22, 2015
Research and Development, Sales and Marketing Cancer, FDA, Inotuzumab ozogamicin, NSCLC, Pfizer, Xalkori, oncology

Pfizer has received two boosts in oncology as Xalkori gets a new breakthrough therapy designation from the FDA, and its …

Merck image

Merck seeks new Keytruda indication in US

April 20, 2015
Sales and Marketing Cancer, FDA, NSCLC, PD-L1, US, keytruda, lung, pembrolizumab

Merck is seeking FDA approval for its successful melanoma drug Keytruda to be used treating lung cancer. The Supplemental Biologics …

astrazeneca image

AstraZeneca lung drug shows promise

April 20, 2015
Sales and Marketing AZ, AZD9291, AstraZeneca, European Lung Cancer Congress, NSCLC, Orphan

AstraZeneca’s non-small cell lung cancer offering AZD9291 has been shown to delay disease progression by over a year. Data presented …

astrazeneca image

FDA grants AstraZeneca immune drug orphan status

April 15, 2015
Sales and Marketing AstraZeneca, FDA, Iressa, MEDI4736, MedImmune, NSCLC, US, gefitinib, non-small cell lung cancer, tremelimumab

The US Food and Drug Administration has granted orphan drug designation to AstraZeneca’s anti-CTLA-4 monoclonal antibody tremelimumab for the treatment …


Merck and Pfizer to co-promote cancer drug

April 9, 2015
Research and Development, Sales and Marketing Cancer, Merck, Merck KGaA, NSCLC, Pfizer, Xalkori, non-small cell lung cancer, oncology

Merck KgaA and Pfizer have agreed to co-promote the latter’s lung cancer treatment Xalkori, and form a new alliance that …

Lilly image

German court rules against Lilly in Alimta patent case

March 10, 2015
Manufacturing and Production, Sales and Marketing ACS, Actavis, Alimta, NICE, NSCLC, lilly, lung cancer, pemetrexed

A German court has ruled that Lilly’s patent for its lung cancer drug Alimta would not be infringed by generic …

Takeda image

Takeda trial hits late-stage buffers

February 17, 2015
Research and Development, Sales and Marketing AMG 706, Japan, NSCLC, Takeda, lung cancer, motesanib

Takeda is to scrap an advanced trial of an investigational drug after it failed to show any benefit in survival …

Lilly image

Lilly, BMS and Merck unite for cancer trials

January 13, 2015
Research and Development, Sales and Marketing BMS, Cancer, Galunisertib, Merck, NSCLC, keytruda, lilly, oncology, opdivo

Lilly will test some of its compounds in combination with rival cancer drugs from Bristol-Myers Squibb and Merck, the companies …

Cyramza  image

Lilly’s lung cancer drug sees FDA approval

December 17, 2014
Sales and Marketing BMS, Cancer, FDA, NSCLC, cyramza, docetaxel, lilly, opdivo, ramucirumab

Eli Lilly’s lung cancer drug Cyramza (ramucirumab) has been shown the green light by the US Food and Drug Administration …

BI image

Boehringer’s lung cancer drug Vargatef sees EU approval

November 28, 2014
Sales and Marketing Boehringer, EU, Europe, IPF, NSCLC, lung cancer, nintedanib, ofev, vargatef

Boehringer Ingelheim’s nintedanib has received its second nod in Europe this month with the European Commission approving it for the …

BMS image

BMS lung cancer drug scores in Phase II

October 31, 2014
Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, FDA, NSCLC, bristol myers-squibb, odivo

Bristol-Myers Squibb is still in the hunt to gain significant market share in the PD-1 therapeutic vaccine race after releasing …

Boehringer image

Boehringer seeks more indications for IPF drug

October 22, 2014
Research and Development, Sales and Marketing Boehringer, IPF, NSCLC, colectoral, crc, nintedanib, ofev

Boehringer Ingelheim’s nintedanib has entered Phase III studies for the treatment of colorectal cancer (CRC), which could add to the …

Latest content